Coronary heart disease stable angina pectoris
Conditions
Interventions
Salvianolate injection group:Salvianolate injection
Aspirin + salvianolate group:Aspirin and salvianolate injection
Sponsors
Xiyuan Hospital, CACMS
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of Western medicine for coronary heart disease and have at least one of the following: (1) The patient has a clear history of old myocardial infarction; (2) Prior coronary revascularization (PCI or CABG); (3) Previous coronary angiography (showing at least one major coronary artery stenosis >=50%); (4) Other noninvasive evidence supporting coronary heart disease (nuclide load test, CT coronary angiography stenosis > 50%); 2. Consistent with the diagnostic criteria for stable fatigue angina; 3. TCM blood stasis syndrome differentiation standard; 4. Canadian Cardiovascular Society (CCS) angina grading I-II; 5. Aged between 35 and 65 years; 6. Patients who have stably taken aspirin enteric-coated tablets (1mg, qd) or salvia polyphenol for injection within the past 1 month; 7. The patients are informed and sign the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Severe heart disease (unstable angina pectoris, acute myocardial infarction within 6 months, severe arrhythmia, etc.), severe cardiopulmonary insufficiency (eg: cardiac function above grade II); 2. Poor hypertension control (systolic blood pressure >=160mmHg or diastolic blood pressure >=100mmHg); 3. Patients with liver, kidney, hematopoietic system and other serious primary diseases, such as liver function (ALT>=2xULN, AST>=2xULN) renal function (Cr > 1.0xULN), and mental illness; 4. Poorly controlled patients with severe diabetes (random blood glucose >=11.1mmol/L); 5. Pregnant or lactating patients or those with pregnancy plans; 6. Participated in other clinical researchers within the past 3 months; 7. Patients who have had surgery in recent 4 weeks and have bleeding tendency; 8. Allergic to this medicine; 9. Patients with mental or physical disabilities; 10. Other conditions deemed unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Butyrylcholin esterase;Acetylcholin esterase;Carboxy lesterase;Catecholoxymethyltransferase;Thromboxane B;6 ketone prostaglandin F1a;Platelet-activated complex 1;IL-1;IL-6;IL-8;TNF-a;Phospholipase A2;ET-1;NO;Vascular endothelial growth factor;Von willebrand factor;Rho-associated coil coil forming protein kinase; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cyclic adenosine phosphate;Cyclooxygenase;Protein kinase A;Vasodilating-stimulating phosphoprotein; | — |
Countries
China
Contacts
Public ContactLi Rui
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed